ATE526409T1 - Humanisierte antikörper spezifisch für sowohl cd45rb als auch cd45ro - Google Patents

Humanisierte antikörper spezifisch für sowohl cd45rb als auch cd45ro

Info

Publication number
ATE526409T1
ATE526409T1 AT02711860T AT02711860T ATE526409T1 AT E526409 T1 ATE526409 T1 AT E526409T1 AT 02711860 T AT02711860 T AT 02711860T AT 02711860 T AT02711860 T AT 02711860T AT E526409 T1 ATE526409 T1 AT E526409T1
Authority
AT
Austria
Prior art keywords
cd45rb
cd45ro
humanized antibodies
antibodies specific
humanized
Prior art date
Application number
AT02711860T
Other languages
English (en)
Inventor
Gregorio Aversa
Frank Kolbinger
Herrera Jose Carballido
Andras Aszadi
Jose Saldanha
Bruce Hall
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE526409T1 publication Critical patent/ATE526409T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02711860T 2001-02-12 2002-02-11 Humanisierte antikörper spezifisch für sowohl cd45rb als auch cd45ro ATE526409T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0103389.3A GB0103389D0 (en) 2001-02-12 2001-02-12 Organic compounds
PCT/EP2002/001420 WO2002072832A2 (en) 2001-02-12 2002-02-11 Therapeutic binding molecules

Publications (1)

Publication Number Publication Date
ATE526409T1 true ATE526409T1 (de) 2011-10-15

Family

ID=9908539

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02711860T ATE526409T1 (de) 2001-02-12 2002-02-11 Humanisierte antikörper spezifisch für sowohl cd45rb als auch cd45ro

Country Status (25)

Country Link
US (1) US20040096901A1 (de)
EP (1) EP1421191B1 (de)
JP (2) JP2004533816A (de)
KR (1) KR100752029B1 (de)
CN (1) CN100529074C (de)
AR (1) AR035539A1 (de)
AT (1) ATE526409T1 (de)
BR (1) BR0207151A (de)
CA (1) CA2437963A1 (de)
CZ (1) CZ20032129A3 (de)
EC (1) ECSP034714A (de)
ES (1) ES2374554T3 (de)
GB (1) GB0103389D0 (de)
HU (1) HUP0401560A3 (de)
IL (1) IL157136A0 (de)
MX (1) MXPA03007197A (de)
NO (1) NO20033549L (de)
NZ (1) NZ548865A (de)
PE (1) PE20020871A1 (de)
PL (1) PL369516A1 (de)
RU (2) RU2405790C2 (de)
SK (1) SK10082003A3 (de)
TW (1) TWI332524B (de)
WO (1) WO2002072832A2 (de)
ZA (1) ZA200305911B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050069538A1 (en) 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
CA2537217A1 (en) * 2003-09-18 2005-03-24 Novartis Ag Therapeutic binding molecules
EP1851308B1 (de) 2005-02-02 2013-08-21 NewSouth Innovations Pty Limited Gegen ein spezifisches antigen aktivierte cd4+ cd25+ t-zellen
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US7855057B2 (en) * 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
WO2008014555A1 (en) 2006-08-02 2008-02-07 Newsouth Innovations Pty Limited Method of identifying cd4+cd25+ t cells activated to an antigen which express cd8
AU2008258646A1 (en) * 2007-06-05 2008-12-11 Fondazione Centro San Raffaele Del Monte Tabor Induction of tolerogenic phenotype in mature dendritic cells
CN102686733A (zh) * 2009-10-16 2012-09-19 陶氏益农公司 树枝状聚合物纳米技术用于将生物分子投递入植物细胞中的用途
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
EP2502631A1 (de) 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immunsuppressor und seine Verwendung
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3026060A1 (de) * 2014-11-26 2016-06-01 Miltenyi Biotec GmbH CD45R0-spezifischer, humanisierter Antikörper oder Fragment davon
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
US20230374148A1 (en) 2020-10-15 2023-11-23 UCB Biopharma SRL Binding molecules that multimerise cd45

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
ES2191702T3 (es) * 1994-03-17 2003-09-16 Merck Patent Gmbh Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
JPH09191886A (ja) * 1996-01-19 1997-07-29 Asahi Breweries Ltd ヒト高親和性ＩｇＥ受容体に対するヒト型化抗体、半キメラ抗体およびキメラ抗体

Also Published As

Publication number Publication date
AR035539A1 (es) 2004-06-02
WO2002072832A3 (en) 2004-03-25
RU2008100239A (ru) 2009-07-20
CN1551919A (zh) 2004-12-01
RU2405790C2 (ru) 2010-12-10
GB0103389D0 (en) 2001-03-28
EP1421191B1 (de) 2011-09-28
KR100752029B1 (ko) 2007-08-28
ES2374554T3 (es) 2012-02-17
CN100529074C (zh) 2009-08-19
US20040096901A1 (en) 2004-05-20
JP2004533816A (ja) 2004-11-11
EP1421191A2 (de) 2004-05-26
CZ20032129A3 (cs) 2003-11-12
RU2328506C2 (ru) 2008-07-10
JP2009034108A (ja) 2009-02-19
IL157136A0 (en) 2004-02-08
ZA200305911B (en) 2004-06-28
SK10082003A3 (sk) 2004-03-02
PE20020871A1 (es) 2002-11-11
WO2002072832A2 (en) 2002-09-19
HK1071769A1 (zh) 2005-07-29
KR20040036684A (ko) 2004-04-30
PL369516A1 (en) 2005-04-18
CA2437963A1 (en) 2002-09-19
NZ548865A (en) 2008-03-28
HUP0401560A3 (en) 2012-09-28
RU2003126168A (ru) 2005-03-10
ECSP034714A (es) 2003-09-24
MXPA03007197A (es) 2003-12-04
BR0207151A (pt) 2004-10-05
NO20033549D0 (no) 2003-08-11
HUP0401560A2 (hu) 2004-11-29
TWI332524B (en) 2010-11-01
NO20033549L (no) 2003-10-10

Similar Documents

Publication Publication Date Title
IS8115A (is) Mótefni sem beint er gegn einkjörnungstogefnaprótíni-1 (MCP-1) og notkun theirra
NO20031642D0 (no) Humaniserte anti-LT-O-R-antistoff
CY2019029I1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY2012019I1 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
DK1297017T3 (da) Sammensætninger og fremgangsmåder med monoklonale og polyklonale antistoffer, der er specifikke for T-cellesubpopulationer
EP1071458A4 (de) Humanisierter antikörper und dessen verwendungen
EE200300509A (et) Antikehad VLA-1 vastu
DK1802658T3 (da) Kimære og humaniserede monoklonale antistoffer mod interleukin-13
EP1572077A4 (de) Verwendungen des monoklonalen antikörpers 8h9
DE60230868D1 (de) Criptoblockierende antikörper und deren verwendung
HRP20151252T4 (hr) Modificirani fab ulomci protutijela
NO20054351D0 (no) Monoklonalt antistoff og hybridom som produserer dette
ATE480564T1 (de) Monoklonaler anti-mensch-tenascin-antikörper
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
NO20034405L (no) Anti-ostepontin-antistoff og anvendelse derav
NO20032542L (no) Dempede anti-CD28-antistoffer og anvendelse derav
NO20025302D0 (no) Aromatase-inhibitorer og monoklonale anti-HER2-antistoffer som antitumormidler
NO20033387D0 (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
FI964845L (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
NO20010747L (no) Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff
DK1664122T3 (da) Terapeutisk humaniserede antistoffer mod CD45-isoformer
DE60045870D1 (de) Monoklonaler antikörper, hybridoma, immuntestverfahren und diagnosekit
DK1263790T3 (da) Monoklonale antistoffer for den humane LDL-receptor, deres produktionsmetode og anvendelse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties